Evaluation of Endpoints for Antifungal Susceptibility Determinations with LY303366

Author:

Klepser Michael E.1,Ernst Erika J.1,Ernst Michael E.1,Messer Shawn A.2,Pfaller Michael A.2

Affiliation:

1. College of Pharmacy, The University of Iowa,1 and

2. Department of Pathology, The University of Iowa Hospitals and Clinics,2Iowa City, Iowa 52242

Abstract

ABSTRACT We have previously reported poor correlation between the in vitro fungicidal activity of LY303366 and MIC results in RPMI medium based upon the manufacturer’s suggested susceptibility endpoint, lack of visual growth. Additionally, we have noted a significant trailing effect with LY303366 when MICs are determined in RPMI medium. These observations have led us to evaluate an alternative susceptibility endpoint for LY303366, an 80% reduction in growth compared with control (similar to that utilized for azoles). Two isolates each of Candida albicans , Candida glabrata , and Candida tropicalis were selected for testing. MICs were determined for LY303366 in RPMI 1640 medium buffered with morpholinepropanesulfonic acid. MICs were determined with suggested (MIC 100 ) and experimental (MIC 80 ) endpoints. The minimal fungicidal concentration (MFC) of LY303366 for each isolate was also determined. Time-kill curves were determined in RPMI medium with each isolate at concentrations of LY303366 ranging from 0.125 to 16× MIC 80 to assess the correlation between MIC 80 and fungicidal activity. Lastly, fungi exposed to LY303366 were examined via scanning electron microscope (SEM) for evidence of drug-induced ultrastructure change. MIC 80 s for test isolates ranged from 0.015 to 0.12 μg/ml and were consistently three to five wells less than MIC 100 s. Good correlation was observed between fungicidal activity, as assessed by kill curves, and the MIC 80 . SEM data revealed significant ultrastructure changes induced by LY303366 even at sub-MIC 80 s. Based on our results demonstrating better correlation between MIC 80 and fungicidal activity, i.e., time-kill curves and MFCs, we suggest that 80% reduction in visible growth be utilized as the endpoint for susceptibility determinations with LY303366 in RPMI medium.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference11 articles.

1. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.;Ernst M. E.;Diagn. Microbiol. Infect. Dis.,1996

2. Klepser M. E. Ernst E. J. Ernst M. E. Messer S. A. Pfaller M. A. Evaluation of the endpoint for antifungal susceptibility determinations with LY303366 abstr. F-71 Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997 158 American Society for Microbiology Washington D.C

3. Growth medium effect on the antifungal activity of LY 303366.;Klepser M. E.;Diagn. Microbiol. Infect. Dis.,1997

4. Klepser M. E. Ernst E. J. Ernst M. E. Lewis R. E. Pfaller M. A. Antifungal time-kill curves influence of test conditions on results abstr. D-144 Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997 109 American Society for Microbiology Washington D.C

5. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3